In a breakthrough for Alzheimer's treatment, US regulators have approved a new drug by Eli Lilly, Kisunla, designed to slow the progression of the disease in its early stages. The Food and Drug Administration (FDA) gave the green light to Kisunla on Tuesday, which is aimed at patients with mild or early dementia from Alzheimer's. The drug works by clearing out brain 'plaque' that leads to memory issues and cognitive haze.
This approval marks only the second time a medication has been shown to slow down cognitive decline, following last year's endorsement of a similar drug by Eisai, a Japanese pharma giant. Kisunla represents a beacon of hope for those battling the initial phase of this devastating disease that erodes memory relentlessly. Bird flu pandemic 'unfolding in slow motion' - fears human infections will rise White House insider breaks silence on Biden after claims he 'just has a cold' While the delay in mental deterioration provided by these drugs is relatively modest about seven months for Lilly's Kisunlapatients and families must weigh the benefits of this extra time against potential downsides, including regular IV infusions and serious side effects like brain swelling.
Alzheimer's experts are hailing the FDA's decision as a monumental step forward after decades of failed attempts. "I'm thrilled to have different options to help my patients," declared Dr. Suzanne Schindler, an Alzheimer's specialist at Washington University in St.
Louis. "It's been difficult as a d.
